I agree, this seems to me to be quite a "good news" day.  With potentially huge market opportunities more clearly defined I don't see money as a big problem but personally I am hoping for a sale sooner than later.  I still believe the further, expeditious, development of RVX's IP will be better served by a BP with deep pockets.

One little bit of potential dot connecting, we don't often talk about it but don't forget Cristoph Boehringer through CD Ventures owns over 1 million shares of RVX.  I think it makes the news of Apabetalone synergy with Jardiance (owned by BoehringerInglheim and Lilly) even a little more interesting.